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CF and SOX proteins belong to the high mobility
group box transcription factor family. Whereas TCFs,
the transcriptional effectors of the Wnt pathway, have
been widely implicated in the development, homeostasis
and disease of the intestine epithelium, little is known
about the function of the SOX proteins in this tissue. Here,
we identiﬁed SOX9 in a SOX expression screening in the
mouse fetal intestine. We report that the SOX9 protein is
expressed in the intestinal epithelium in a pattern charac-
T
 
teristic of Wnt targets. We provide in vitro and in vivo evi-
dence that a bipartite 
 
 
 
-catenin/TCF4 transcription factor,
the effector of the Wnt signaling pathway, is required for
SOX9 expression in epithelial cells. Finally, in colon epi-
thelium-derived cells, SOX9 transcriptionally represses the
 
CDX2
 
 and 
 
MUC2
 
 genes, normally expressed in the mature
villus cells of the intestinal epithelium, and may therefore
contribute to the Wnt-dependent maintenance of a progen-
itor cell phenotype.
 
Introduction
 
Proliferation, differentiation, and migration of cells must be
coordinately regulated to maintain the integrity of the contin-
uously renewing intestine epithelium. This epithelium consists
of a proliferative compartment, the crypt of Lieberkühn, and
a differentiated, functional compartment, consisting of the
villus in the small intestine and the luminal surface in the
colon. Multipotent stem cells, located near the bottom of
the crypts, generate new cells which migrate to the villus
while differentiating into enterocyte, goblet, and enteroen-
docrine cells. In the small intestine, a fourth cell type, the
Paneth cells, migrates downward and settles at the bottom of
the crypts as terminally differentiated cells (Potten and Moeffler,
1990; Stappenbeck et al., 1998).
Extracellular signals, including Wnt molecules, are required
for this organization of the intestine epithelium. Upon bind-
ing of a secreted Wnt molecule to its corresponding Frizzled
receptor, the canonical Wnt pathway is activated, resulting
in the stabilization and accumulation of 
 
 
 
-catenin in the
nucleus. Interaction with 
 
 
 
-catenin activates the TCF/LEF
transcription factors, resulting in transcription of target
genes (Brantjes et al., 2002). In the intestine, the Wnt sig-
naling pathway has been implicated in the regulation of the
proliferation/differentiation balance (van de Wetering et al.,
2002). Consistent with this, no proliferation can be detected,
and all epithelial cells appear differentiated, in the intestine
of mice null for TCF4, the main Wnt pathway transcription
factor in the intestinal epithelium (Korinek et al., 1998).
The Wnt pathway also regulates the expression of the Eph/
Ephrin surface molecules, responsible for the ordered posi-
tioning of epithelial cells along the crypt-villus axis (Batlle et al.,
2002). In addition, Wnt signals control the differentiation
of the secretory cell lineage of the epithelium, because over-
expression of the Wnt-pathway inhibitor Dickkopf1 blocks
differentiation of the Paneth, goblet, and enteroendocrine
cell types (Pinto et al., 2003). Finally, mutations in compo-
nents of the Wnt pathway, including the tumor suppressor
APC and the multifunctional 
 
 
 
-catenin protein, are found
in the vast majority of colon cancers (Morin et al., 1997).
Such mutations result in stabilization of 
 
 
 
-catenin, which
then continuously interacts with TCF4, leading to constitutive
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activation of target genes (Korinek et al., 1997). Moreover,
targeted mutations of APC or 
 
 
 
-catenin are sufficient to ini-
tiate tumorigenesis in the mouse (Fodde et al., 1994; Shi-
bata et al., 1997; Harada et al., 1999), highlighting the im-
portance of the Wnt pathway in the development of cancer.
The diversity of cellular processes involving Wnt signals
suggests branching of the pathway to permit specific cell re-
sponses. However, evidence for such branch-determining fac-
tors, each mediating part of the Wnt response downstream of
the TCF/LEF transcription factors, is presently lacking.
The TCF/LEF transcription factors share a common high
mobility group DNA binding domain with the SOX tran-
scription factors. Similarly to TCFs, SOX proteins have
been widely implicated in the establishment of cell multipo-
tency (Avilion et al., 2003; Kim et al., 2003), cell commit-
ment (Mori-Akiyama et al., 2003; Stolt et al., 2003), and
differentiation (Kamachi et al., 2000; Stolt et al., 2002).
Here, we screened the intestine epithelium for expressed
SOX genes to investigate the possibility of a functional link
with the related Tcf factors. This unexpectedly led to the
identification of SOX9.
SOX9 function is best known for its essential roles in
chondrogenesis (Foster et al., 1994; Wagner et al., 1994;
Wright et al., 1995; Bi et al., 1999, 2001) and the develop-
ment of the male gonad (Foster et al., 1994; Wagner et al.,
1994; Kent et al., 1996; Südbeck et al., 1996). SOX9 is also
involved in the development of the neural crest (Spokony et
al., 2002) and of the spinal cord glial cells (Stolt et al.,
2003). Strikingly, SOX9 controls the transcription of target
genes which are specific for each process: in chondrogenesis,
it regulates the cartilage specific genes Col2a1 (Bell et
al., 1997; Lefebvre et al., 1997; Bi et al., 1999), Col11a2
(Bridgewater et al., 1998), Aggrecan (Sekiya et al., 2000),
and campomelic dysplasia (CD)–RAP (Xie et al., 1999).
During male gonad development, it controls the expression
of the anti-Müllerrian hormone gene (de Santa Barbara et
al., 1998). In the neural crest, the expression of the tran-
scription factor Slug depends on SOX9 (Spokony et al.,
2002), whereas SOX9 target genes remain to be identified in
the spinal cord.
Here, we report the expression of SOX9 in an addi-
tional structure, the intestinal epithelium. We show that
this SOX9 expression depends on the activity of the Wnt
pathway and that SOX9 is involved in repression of differ-
entiation genes, including the homeobox gene CDX-2
and the MUC-2 gene, encoding the main intestinal mu-
cin, a major constituent of the mucous gel covering the
digestive tract surface.
 
Results
 
Screening for 
 
SOX
 
 genes expressed in the mouse intestine
 
RT-PCR was performed with mouse neonate intestine, us-
ing degenerate oligonucleotide primers (Cremazy et al.,
1998). The amplified products were cloned and sequenced,
leading to the identification of 
 
SOX3
 
, 
 
SOX4
 
, 
 
SOX5
 
, 
 
SOX7
 
,
 
SOX9
 
, and 
 
SOX18
 
. Northern blot analysis revealed that
 
SOX9
 
 mRNA was strongly expressed not only during devel-
opment, but also in the adult intestine, and represented the
prominent gene among the identified set of expressed 
 
SOX
 
genes (unpublished data). In consequence, further studies
were focused on 
 
SOX9
 
.
 
SOX9 is expressed in the proliferative compartment of 
the intestinal epithelium
 
In the mouse intestine, the SOX9 protein is robustly ex-
pressed from the duodenum to the distal colon (Fig. 1 a).
SOX9 expression is restricted to the nuclei of the immature
cells constituting the proliferative compartment of the epithe-
lium (Fig. 1, b, d, and f) and almost perfectly overlaps with
that of Ki-67, a proliferation marker (Fig. 1, c, e, and g). In
the fetal intestine, crypts are not developed and the prolifera-
tive cells are found in the intervillus region (Fig. 1 c), whereas
in the adult intestine, proliferation is restricted to the lower
half of the crypts of Lieberkühn (Fig. 1, e and g). In addition
to the proliferative compartment, SOX9 expression was ob-
Figure 1. SOX9 is expressed in the proliferative compartment of 
the epithelium. (a) Western blot with mouse tissue samples repre-
sentative of the overall length of the intestine (5  g protein/lane). 
Antibodies used are indicated. (b) Immunohistochemistry with neonate 
and adult intestine samples. In the neonate mouse, the architecture 
of the intestine is not complete, crypts are not formed and the prolif-
erative, Ki-67 positive, compartment is restricted to the intervillus 
region (top). In the adult small intestine, crypts are invaginated 
between the villi in the underlying mesenchyme (middle). In the 
adult colon, crypts contain more cells, villi are absent and the 
differentiated compartment constitutes the flat luminal surface of 
the epithelium. Cells constituting the proliferative compartment 
are positive for both SOX9 and Ki-67 (arrows). Arrowheads point 
at Paneth cells, positive for SOX9 and negative for Ki-67. Bars: (b–e) 
50  m; (f and g) 40  m. 
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served in the nuclei of the Paneth cells, located at the bottom
of the crypts of Lieberkühn of the adult small intestine (Fig. 1
d). As these cells are postmitotic and fully differentiated, they
do not express the Ki-67 antigen (Fig. 1 e). In addition to the
SOX9 nuclear staining, a weak cytoplasmic staining is visible
in the same sections. As the subcellular localization of SOX9
is regulated in some structures, such as the gonad (Smith and
Koopman, 2004), we tested whether the intestinal epithe-
lium cytoplasmic staining was specific, using Western blot
analysis of nuclear and cytoplasmic subcellular fractions
of mouse intestine epithelial cells and of human cultured
HT29-16E cells. This revealed that SOX9 is present only in
the nuclear fraction (Fig. S1, available at http://www.jcb.org/
cgi/content/full/jcb.200311021/DC1), thus demonstrating
that the faint cytoplasmic signals obtained with the anti-
SOX9 antibody throughout the intestine epithelium (Fig. 1,
d and f) is nonspecific.
The SOX9 expression pattern strikingly matches the do-
main of the epithelial cells stimulated by Wnt molecules,
where nuclear 
 
 
 
-catenin can interact with TCF4 to activate
transcription (van de Wetering et al., 2002). Although the
Wnt pathway controls multiple aspects of intestine epithe-
lium physiology, little is known about downstream tran-
scription factors. This prompted us to test whether the
SOX9 transcription factor is regulated by the Wnt pathway
and constitutes one of its downstream effectors.
 
SOX9 expression in human colon carcinomas
 
As SOX9 is expressed in cells in which the Wnt signaling
pathway is active, we anticipated strong SOX9 expression in
cancer cells where there is constitutive activation of the Wnt
pathway. We first tested SOX9 expression in human colon
cancer–derived cell lines containing activating mutations of
components of the Wnt pathway, which result in constitu-
tive expression of 
 
 
 
-catenin/TCF4 target genes (Korinek et
al., 1997). In all the colon cancer cell lines we tested (DLD-1,
LS174T, SW480, TC-7, and HT29), SOX9 mRNA (not
depicted) and protein were strongly expressed (Fig. 2 a). In
contrast, SOX9 expression was hardly detectable in HEK293
cells, a nonintestinal epithelial cell line.
In the healthy human colon epithelium, the expression of
SOX9 is restricted to the proliferative, lower half of the crypt
(Fig. 2 b). Analysis of sections from human colorectal ade-
nocarcinomas revealed that SOX9 is strongly expressed in
specific regions of the lesion (Fig. 2 c). We then asked
whether this pattern corresponded to cells where there is an
active 
 
 
 
-catenin–TCF4 complex, driving aberrant transcrip-
tion of target genes. Such cells can be identified because they
contain cytoplasmic and nuclear 
 
 
 
-catenin (Korinek et al.,
1997). When we stained serial sections for 
 
 
 
-catenin, it was
clear that the same structures that strongly expressed SOX9
also contain cytoplasmic and nuclear 
 
 
 
-catenin (Fig. 2, c
and d). This result again correlates SOX9 expression with
activity of the 
 
 
 
-catenin–TCF4 complex and suggests that
SOX9 expression might be driven by this complex.
 
SOX9 expression is controlled by the Wnt pathway in 
human colon carcinoma cells
 
To test this hypothesis further, we overexpressed a dominant
negative TCF4 mutant (
 
 
 
NTCF4) in the LS174T human
colon carcinoma cell line. This NH
 
2
 
-terminally deleted mu-
tant lacks the 
 
 
 
-catenin-interaction domain and has been
shown to interfere with the activity of the endogenous, con-
stitutively active, 
 
 
 
-catenin–TCF4 complex present in these
cells (van de Wetering et al., 2002). Cells were transfected
with either the 
 
 
 
NTCF4 or a mock GFP expression con-
struct and the endogenous SOX9 protein expression was
monitored by immunofluorescence. As expected, overex-
pression of GFP did not affect the SOX9 nuclear staining in
transfected LS174T cells, compared with adjacent nontrans-
fected cells (Fig. 3, a, e, and i). In contrast, overexpression of
 
 
 
NTCF4 always resulted in undetectable endogenous nu-
clear SOX9. A typical result in shown in Fig. 3 (b, f, and j).
This indicates that the 
 
 
 
-catenin–TCF4 complex activity is
required for SOX9 expression.
To rule out the possibility that the overexpressed
 
 
 
NTCF4 protein might interfere with DNA binding of
non-TCF proteins, we overexpressed the cytoplasmic do-
main of E-cadherin (cyt-E-cadherin), which has been re-
ported to sequester signaling-competent 
 
 
 
-catenin, thus
abrogating the 
 
 
 
-catenin–TCF4 transcriptional activity
(Gottardi et al., 2001; Simcha et al., 2001). As expected,
overexpression of a GFP–cyt-E-cadherin construct in LS174T
cells resulted in a strong decrease of nuclear 
 
 
 
-catenin stain-
ing, which then colocalized with the GFP–cyt-E-cadherin
fusion in a perinuclear pattern (Fig. 3, c, g, and k). Accord-
ingly, SOX9 expression was abolished in the nucleus of all
the GFP–cyt-E-cadherin transfected cells, as exemplified in
Fig. 3 (d, h, and l). Hence, an active 
 
 
 
-catenin–TCF4 com-
Figure 2. SOX9 is expressed in various colon carcinoma cell lines. 
(a) Western blot with cell extracts from a panel of human colon 
carcinoma cell lines (1  g/lane) and the nonintestinal epithelial cell 
line HEK293. Endogenous SOX9 protein was detected in all colon 
carcinoma–derived cell lines but not in HEK293. HEK293 cells, 
transiently transfected with SOX9, were used as a positive control. 
(b–d). Immunohistochemistry with sections of human colon. (b) 
SOX9 staining in healthy colon epithelium; (c) SOX9 staining in 
adenocarcinomatous colon; (d)  -catenin staining in adenocarcino-
matous colon. Arrows point at cells expressing the indicated proteins. 
Bars: (b) 50  m; (c and d) 80  m. 
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plex is required for expression of the SOX9 protein in colon
carcinoma cells.
We found that this regulation of SOX9 occurs at the
RNA level using LS174T human colon carcinoma cells sta-
bly transfected with an inducible 
 
 
 
NTCF4 construct (van
de Wetering et al., 2002). As noted above, LS174T cells ex-
press high levels of endogenous SOX9 mRNA and protein.
This mRNA expression level was strongly reduced after ex-
pression of 
 
 
 
NTCF4 (Fig. 3 m). Phosphorimager quan-
tification of SOX9 hybridization signals, after normaliza-
tion with the GAPDH hybridization signals, indicated that
SOX9 expression is down-regulated by 
 
 
 
50% (Fig. 3 n).
The expression of the SOX9 protein was also significantly
decreased after induction of the expression of the 
 
 
 
NTCF4
construct (Fig. 3 o). The quantitative difference in the
SOX9 repression, using transient versus stable transfection
of Wnt-interfering constructs, likely reflects the levels of ex-
pression of these constructs and their dominant negative
mode of action.
 
Repression of SOX9 occurs rapidly upon interference 
with the 
 
 
 
-catenin–TCF4 activity
 
We wanted to determine whether the repression of SOX9 is
an early consequence of the arrest of Wnt signaling, or if it is
a more long-term, indirect consequence of the global alter-
ation of cell physiology. LS174T cells were transfected with
either GFP or GFP–cyt-E-cadherin in order to interfere
with Wnt signaling, and the SOX9 protein was visualized by
immunofluorescence after 0, 8, 16, 24, 32, 40, and 48 h.
Fig. S2, available at http://www.jcb.org/cgi/content/full/
jcb.200311021/DC1, shows that as soon as the GFP–cyt-
E-cadherin construct became detectable (8 h), it resulted in a
decrease of SOX9 expression in most of the transfected cells.
After 16 h, all the cells expressing GFP–cyt-E-cadherin had
hardly detectable nuclear SOX9. In contrast, transfection of
GFP alone did not alter the SOX9 staining, even after 48 h.
Thus, interference with the activity of the 
 
 
 
-catenin–TCF4
complex results in a rapid decrease of the expressed SOX9
protein. We conclude that SOX9 is a physiological target of
Wnt signaling.
 
Nuclear SOX9 expression is lacking in the intestine 
epithelium of TCF4 null mice
 
The Wnt–
 
 
 
-catenin–TCF4 pathway is necessary for the
maintenance of a functional crypt-villus axis in the mouse
intestinal epithelium (Pinto et al., 2003). The gene knock-
out of its transcriptional effector, TCF4, leads to the loss of
the proliferative compartment of the epithelium. As a conse-
quence, TCF4 null mice die perinatally (Korinek et al.,
1998). As the Wnt signaling pathway is essential for SOX9
expression in cultured cells, we expected that SOX9 expres-
Figure 3. The Wnt– -catenin–Tcf pathway is required for SOX9 
expression in colon epithelial cells. (a–l) Immunofluorescence in 
transiently transfected LS174T colon carcinoma cells, fixed 36 h 
after transfection. (a–d) Hoechst nuclear staining. (e) GFP. (f) Detec-
tion of exogenous Myc-tagged  NTCF4 in transfected cells with an 
anti-Myc antibody. (g and h) GFP shows the perinuclear accumulation 
of the GFP–cyt-E-cadherin fusion in transfected cells. (i) Identical 
SOX9 staining in GFP-transfected and nontransfected cells. (j and l) 
SOX9 staining is absent in cells transfected with the Wnt pathway 
interfering constructs  NTCF4 and GFP–cyt-E-cadherin. (k)  -Catenin 
is efficiently sequestered by GFP–cyt-E-cadherin, as shown by their 
identical distribution in transfected cells. The type of staining is 
indicated on each panel. (m) Northern blot. SOX9 mRNA detection 
in LS174T colon carcinoma cells stably transfected with an inducible 
 NTCF4 construct. Time of doxycyclin induction is indicated for 
both the control and the  NTCF4 expressing cell line. A GAPDH 
probe was used as a loading control. (n) Phosphorimager quantification 
of the Northern blot signals. (o) Western blot. Detection of the 
SOX9 protein in the  NTCF4 stably transfected LS174T cells with 
or without doxycycline induction. Bar, 15  m.
Figure 4. Absence of the SOX9 protein in the proliferative compart-
ment of TCF4-deficient neonate mouse. (a and b) TCF4 heterozygous 
mice are healthy and fertile. The actively proliferating intervillus 
cells are Ki-67 positive and express abundant nuclear SOX9 protein 
(arrows). (c and d) In TCF4 null mice, no Ki-67 positive proliferating 
cells can be found in the intervillus region (arrowheads), and SOX9 
expression is completely abrogated. Bar, 5  m. 
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sion would be disrupted in the intestinal epithelium of
TCF4 null mice. Indeed, when we examined the intestine of
neonate TCF4 knockout mice, the SOX9 protein was unde-
tectable in the nucleus of epithelial cells, in contrast to
TCF4 heterozygous littermates where SOX9 was correctly
expressed in the proliferative, Ki-67 positive, intervillus re-
gion of the intestine epithelium (Fig. 4). Therefore, TCF4-
mediated Wnt signaling is required for appropriate SOX9
expression in the mouse intestine epithelium.
 
SOX9 represses 
 
CDX2
 
 and 
 
MUC2
 
, two genes 
associated with differentiation
 
As SOX9 encodes a transcription factor, and its expression
is regulated by the Wnt–
 
 
 
-catenin–TCF4 pathway, we hy-
pothesized that it might mediate all or part of the Wnt re-
sponse in intestine epithelial cells. To test this, we trans-
fected human LS174T cells, which contain an endogenous
constitutively active 
 
 
 
-catenin–TCF4 complex, and there-
fore endogenous SOX9, with wild-type, antisense, or domi-
nant-negative SOX9 (
 
 
 
C-SOX9) constructs and GFP. For
these experiments, cells were cotransfected with the plasmid
pMACS-K
 
k
 
, which allowed efficient selection of transfected
cells. We then screened by RT-PCR a panel of previously
reported Wnt–
 
 
 
-catenin–TCF4-regulated genes (van de
Wetering et al., 2002). This led to the identification of
both SOX9-dependent and SOX9-independent Wnt target
genes (Fig. 5), indicating branching of the Wnt response,
which might explain how the Wnt pathway can exert a
wide spectrum of cellular effects. CDX1/-2 genes, both ho-
mologues of the 
 
Drosophila
 
 homeobox Caudal gene (Du-
prey et al., 1988; Suh et al., 1994), exemplified such
branching. In the intestinal epithelium, the CDX1 tran-
scription factor is mostly expressed in the crypts whereas
CDX2 is mostly active on the villi (Subramanian et al.,
1998; Silberg et al., 2000). Both genes are thought to be
important for the antero-posterior patterning of the intesti-
nal epithelium and in defining patterns of proliferation and
differentiation along the crypt-villus axis (Silberg et al.,
2000). CDX1/-2 are, respectively, positively and negatively
regulated by the Wnt pathway. Indeed, coculture experi-
ments, as well as loss of CDX1 expression in the gut of
TCF4-deficient mice, led to the conclusion that 
 
CDX1
 
 is a
target of the Wnt–
 
 
 
-catenin–TCF4 pathway (Lickert et al.,
2000; Ikeya and Takada, 2001). On the other hand, APC
up-regulates CDX2 (da Costa et al., 1999), although the
signaling pathway downstream of APC has not yet been
elucidated. In our experiment, 
 
CDX1
 
 expression was not al-
tered by gain/loss of SOX9 function in LS174T cells, in
contrast with 
 
CDX2
 
 expression which was down-regulated
when SOX9 was overexpressed. Conversely, 
 
CDX2
 
 expres-
sion increased when we overexpressed the antisense or the
 
 
 
C-SOX9 constructs (Fig. 5). We then monitored 
 
CDX2
 
promoter activity using a human 
 
CDX2
 
 promoter-lucif-
erase reporter construct, cotransfected together with the
various 
 
SOX9
 
 constructs or with the 
 
 
 
NTCF4 construct.
Again, SOX9 overexpression resulted in a decrease of the
promoter activity, whereas interfering with the endogenous
SOX9 function, either directly with 
 
 C-SOX9 or SOX9
Figure 5. SOX9 represses intestine epithelium differentiation genes. 
LS174T cells were transiently transfected with GFP, Flag-SOX9 fusion, 
Flag-SOX9 antisense, or Flag-COOH–truncated SOX9 ( C-Sox9) con-
structs, and the expression of the indicated putative target genes was 
monitored by RT-PCR. The primers used are listed in Table S1.
Figure 6. SOX9 negatively regulates the promoters 
of the CDX2 and MUC2 genes. LS174T cells were 
cotransfected, in triplicate, with the indicated 
expression constructs (10 and 100 ng) together 
with CDX2-luciferase, MUC2-luciferase and SOX-
luciferase reporters (500 ng) and relative luciferase 
activities were measured 36 h after transfection. 
The reporter activity in mock-transfected cells was 
arbitrarily set to 100. (a) CDX2 and MUC2 promoters 
regulation by SOX9; (b–d) SOX9-VP16 recapitulates 
the transcription regulation properties of the wild-
type SOX9 on SOX-luciferase (b), CDX2-luciferase 
(c), and MUC2-luciferase constructs (d). The histo-
grams represent mean values of triplicate experi-
ments and SDs are shown with error bars.42 The Journal of Cell Biology | Volume 166, Number 1, 2004
antisense constructs, or indirectly with the  NTCF4 con-
struct, strongly increased CDX2 promoter activity (Fig. 6
a). We conclude that SOX9 is involved in the regulation of
CDX2 but not CDX1, which is consistent with previous re-
ports showing that CDX1 is a direct transcriptional target
of the  -catenin–TCF4 complex (Lickert et al., 2000).
c-Myc has also been described as a direct  -catenin–TCF4
target (He et al., 1998), but its expression level is not al-
tered neither by SOX9 gain/loss of function (Fig. 5). Sev-
eral SOX9-dependent genes are down-regulated in cells
overexpressing SOX9 and up-regulated in cells where
SOX9 function is challenged. In addition to CDX2 and its
target gene MUC2 (Yamamoto et al., 2003; Figs. 5 and 6
a), there was slight but reproducible SOX9-dependent
down-regulation of genes encoding the differentiation
markers  Fabp-i and Galectin-4 (not depicted). This ex-
periment indicates that SOX9, which is expressed in the
crypt proliferative compartment of the epithelium, represses
genes expressed in the villus compartment, encoding mark-
ers of differentiated cells. Indeed, the constitutive Wnt–
 -catenin–TCF4-mediated repression of these genes is
abrogated when SOX9 function is disrupted, using either
antisense or dominant-negative constructs. Hence, SOX9
function might contribute to the Wnt-dependent mainte-
nance of an undifferentiated progenitor phenotype in the
intestinal epithelium by repressing differentiation genes
such as CDX2 and MUC2. TCF4 gene expression, in turn,
was not modulated by SOX9 (Fig. 5).
To confirm these data, we constructed a cell line derived
from the human colon adenocarcinoma cell line HT29-
16E, in which we stably introduced a doxycycline-induc-
ible flag-SOX9 construct. Doxycycline induction of Flag-
SOX9 caused the decline of endogenous CDX2 and MUC2
gene expression (unpublished data), confirming the data
obtained above in transiently transfected LS174T cells. To
further address the role of SOX9 in a living animal context,
we induced in vivo tumor formation by grafting HT29-
16E-SOX9 cells subcutaneously in nude mice (Fig. 7). In
nondoxycycline-treated mice (n     3), the resulting tu-
mors, grown over 11 wk, were anatomically heterogeneous,
with mucinous tubular structures (Fig. 7 a) together with
poorly differentiated and poorly organized structures (Fig.
7 d). In these tumors, we failed to detect Flag-SOX9. Nu-
clear CDX2 as well as MUC2 production were found in
the tubular structures, whereas these proteins were hardly
detected in the poorly organized structures (Fig. 7, b, c, e,
and f). Identical pictures were obtained after MUC2 anti-
body staining and alcian blue staining of mucins (unpub-
lished data). In animals induced with doxycycline for 10
wk (n     3), the secreting tubular structures were not
readily found (Fig. 7, a, g, and j). Flag-SOX9 was detected
in some areas of the tumor, and in these areas, there was no
expression of CDX2 nor of MUC2 (Fig. 7, g–l). Weak
CDX2 staining could, however, occasionally be observed
in doxycycline-treated mice but only in structures where
the SOX9 transgene expression could not be detected. We
conclude from these data that SOX9 inhibits CDX2 and
MUC2 protein expression both in intestinal adenocarci-
noma cells cultures in vitro and in living animals grafted
with tumor cells.
SOX9-mediated repression of CDX2 and MUC2 
involves intermediate activation of a repressor protein
Although SOX9 is known as a transcriptional activator, it
represses the expression of the target genes identified in this
work. In consequence, SOX9 may either act as a repressor in
the intestinal epithelium, or activate transcription of an in-
termediate transcription repressor. To discriminate between
these two possibilities, we analyzed the luciferase activity
driven by the CDX2 and MUC2 promoters in LS174T cells,
transfected with wild-type SOX9,  C-SOX9, and a domi-
nant-activating SOX9 protein in which the transcription ac-
tivation domain of SOX9 has been replaced with that of the
VP-16 viral transactivator, making this chimeric protein a
forced transcription activator. Fig. 6 (b–d) shows that the
SOX9-VP16 fusion protein mimics all the aspects of SOX9
transcription regulation properties that we analyzed: it
strongly activates transcription through a synthetic enhancer
containing multimerized SOX binding sites and represses
the promoters of the CDX2 and MUC2 differentiation genes
to a similar extent as the wild-type SOX9. This implies that
the SOX9-mediated repression of CDX2 and MUC2 in-
volves prior transcriptional activation of an as-yet unidenti-
fied repressor gene.
Discussion
SOX9 was first described as the gene responsible, when het-
erozygously mutated, for the skeletal malformation syn-
drome, CD, which is sometimes associated with XY sex re-
versal (Foster et al., 1994; Wagner et al., 1994). Of note, no
Figure 7. SOX9 represses CDX2 and MUC2 in xenograft-derived 
tumors. Sections from tumors resulting from xenografts of HT29-16E-
SOX9 cells, stained with antibodies against the Flag tag, the CDX2 
and MUC2 proteins. Antibodies used for staining are indicated. The 
expression of the Flag-SOX9 construct is detected uniquely in 
the nucleus of tumors from doxycycline-fed mice. Bar, 130  m.SOX9 mediates a branch of the Wnt response | Blache et al. 43
intestinal epithelium defect has been reported to date in CD
patients, indicating that SOX9 haploinsufficiency may not
be critical in this tissue. More recently, SOX9 was found to
be essential for the development of the neural crests and the
central nervous system (Xie et al., 1999; Spokony et al.,
2002; Mori-Akiyama et al., 2003). Here, we report that
SOX9 is also expressed in the intestinal epithelium. In this
highly organized structure, the SOX9 protein is only ex-
pressed in the lower third of the crypts of Lieberkühn, in
both the small intestine and colon. However, whereas the
lower part of the colonic crypts constitute the proliferative
compartment of the epithelium, the situation is different in
the small intestine. Paneth cells, which occupy the bottom
of the small intestine crypts, beneath the cells constituting
the proliferative compartment, are postmitotic, fully differ-
entiated cells (Cheng, 1974). Thus, SOX9 is expressed in
proliferative cells, which probably include the stem cells, as
well as in the terminally differentiated Paneth cells. This
suggests that SOX9 expression is not restricted either to a
single cell type or to the proliferation state. Rather, it corre-
sponds to a location, the bottom of the crypt, which is also
considered to be the cellular “niche” of the epithelium,
where cells contain nuclear  -catenin in response to Wnt
signaling (Batlle et al., 2002; van de Wetering et al., 2002).
The nature of the  -catenin–TCF4-dependent 
regulation of SOX9
In addition to the similar pattern of SOX9 and nuclear
 -catenin expression along the crypt-villus axis, we demon-
strate that SOX9 expression in the intestinal epithelium de-
pends on the canonical Wnt– -catenin–TCF pathway. In
cultured human colon carcinoma cell lines, SOX9 expres-
sion was strictly dependent on the activity of the TCF4–
 -catenin complex. In vivo, SOX9 expression could no longer
be detected in the intestinal epithelium of TCF4-null mice,
whereas it was strongly expressed in human colon carcino-
mas, which contain a constitutive  -catenin–TCF4 com-
plex. Given the striking overlap between SOX9 expressing
cells and Wnt-stimulated cells on the one hand, and the ex-
perimental evidence that SOX9 expression depends on
TCF4– -catenin transcriptional activity on the other, we
conclude that SOX9 constitutes a physiological target of the
Wnt– -catenin–TCF4 pathway in the intestinal epithelium.
This regulation of SOX9 expression by the Wnt pathway
might or might not depend on a direct interaction of TCF
with the SOX9 promoter. In an attempt to clarify this, we
cloned a human genomic DNA fragment, spanning 2.6 kb
upstream of the SOX9 transcription start site, into a lu-
ciferase reporter plasmid. This fragment did not contain a
canonical TCF binding sequence (ATCAAAGG), but con-
tained several noncanonical TCF binding sites, such as de-
scribed, for instance, in the Siamois (Brannon et al., 1997)
and Cyclin D1 (Tetsu and McCormick, 1999) promoters.
However, the basal luciferase activity driven by this 2.6-kb
SOX9 promoter fragment in LS174T colon carcinoma cells
was not modulated by cotransfected  NTCF4 (unpublished
data). We conclude that our construct does not contain
functional TCF binding sites, which still does not exclude
the possibility that TCF transcription factors might directly
regulate the SOX9 promoter. Indeed, although this pro-
moter has been poorly characterized, scattered regulatory en-
hancer elements have been detected up to 1 megabase up-
stream of the human SOX9 transcriptional unit (Wunderle
et al., 1998; Bishop et al., 2000). We performed in silico
screening of the genomic region situated from 200 kb up-
stream to 100 kb downstream of the SOX9 transcriptional
unit for putative canonical TCF binding sites. Although sev-
eral putative sites were identified, the closest mapped at 15
kb upstream of SOX9 (unpublished data). This means that a
direct regulation of SOX9 by the Wnt effector TCF4 is pos-
sible but that the formal identification of a Wnt responsive
element in the SOX9 promoter region would require a long
range in vivo analysis of the SOX9 promoter in transgenic
animals.
In an alternative model, the Wnt regulation of SOX9
might involve one or several intermediate transcription fac-
tors, such as CDX-1 or c-MYC, which have already been de-
scribed as direct Wnt targets (He et al., 1998; Lickert et
al., 2000) and are not regulated by SOX9 in our RT-PCR
experiment.
Although the direct/indirect status of the Wnt regulation
of SOX9 remains unclear, we showed that down-regulation
of the SOX9 protein occurs rapidly after interference with
the Wnt pathway activity, i.e., as soon as the expression of
the interfering protein factor can be detected. This indicates
that SOX9 down-regulation does not result from a indirect,
long-term modification of cell physiology initiated by the ar-
rest of Wnt signaling, but represents a direct or early physio-
logical response to this arrest.
Interestingly, overexpressing the SOX9 protein in 293 ep-
ithelial cells resulted in a strong decrease of the  -catenin–
TCF activity (Fig. S3, available at http://www.jcb.org/cgi/
content/full/jcb.200311021/DC1), suggesting that SOX9
might also mediate a negative feedback loop on the  -cate-
nin–TCF activity to fine tune the level of transcriptional ac-
tivity of the Wnt pathway.
Wnt-regulated SOX9 function outside of the 
intestine epithelium?
A study of the transcriptional response of NCCIT human
embryonal carcinoma cells to the Wnt-3a signal identified
SOX9 as one of the genes which was up-regulated upon
Wnt-3a signaling (Willert et al., 2002). Such Wnt-regula-
tion of SOX9 thus might also exist in additional structures
where SOX9 expression has been reported. For instance, in
chondrogenesis, Wnt-4 signals through the  -catenin–TCF-
LEF pathway to accelerate chondrogenesis (Hartmann and
Tabin, 2000), a process in which SOX9 function is essential
(Bi et al., 1999; Akiyama et al., 2002). Moreover, in the de-
veloping mouse limb buds, the expression patterns of SOX9
and of the Wnt-antagonist Dickkopf are mutually exclusive
(Grotewold and Ruther, 2002). Wnt signals are also in-
volved in the development of the neural crests (Yanfeng et
al., 2003), where SOX9 has also recently been found to be
required (Spokony et al., 2002; Cheung and Briscoe, 2003;
Mori-Akiyama et al., 2003). It will be interesting to deter-
mine whether Wnt signals are involved in the regulation of
SOX9 in such structures.44 The Journal of Cell Biology | Volume 166, Number 1, 2004
The SOX9 transcriptional activator represses 
differentiation genes
Our small-scale screening of Wnt target genes for possible
regulation by SOX9 identified both SOX9-regulated and
SOX9-independent Wnt target genes. This indicates that
the cellular response to Wnt signaling branches at the level
of downstream transcription factors and that SOX9 deter-
mines one of these branches, probably involved in the main-
tenance of undifferentiated cells.
Strikingly, this experiment only revealed genes expressed
in the differentiated cells of the epithelium, the expression of
which is repressed by SOX9 expression. For instance, SOX9
represses the expression of the CDX2 transcription factor,
known to be mostly active in villus cells (Silberg et al., 2000;
Rings et al., 2001) and to promote cell differentiation by ac-
tivating transcription of genes encoding typical differentia-
tion markers, including MUC2, sucrase-isomaltase, and lac-
tase (Lorentz et al., 1997; Yamamoto et al., 2003). To date,
SOX9 has generally been described as a transcriptional acti-
vator (Südbeck et al., 1996; Bell et al., 1997; Lefebvre et al.,
1997; Ng et al., 1997; de Santa Barbara et al., 1998; Liu et
al., 2000; Sekiya et al., 2000; Liu et al., 2001; Panda et al.,
2001), although it was recently found to mediate a dual
transcriptional effect on the COL2A1 gene, depending on
the promoter elements involved (Kypriotou et al., 2003). In-
terestingly, recent studies in the central nervous system
showed that SOX1, SOX2, and SOX3 act as repressors of
postmitotic neuronal markers. In this case, SOX1–3 inhibit
neurogenesis by activating transcription and, conversely, re-
pression of their as yet unknown target genes facilitates neu-
ronal differentiation (Bylund et al., 2003). Here, we show
that a forced activator version of SOX9 (SOX9-VP16) mim-
ics the properties of wild-type SOX9, which suggests an
analogous situation, where the intermediate activation of a
repressor transcription factor mediates the repression of dif-
ferentiation genes.
Because one reported role of the Wnt pathway is the
maintenance of an undifferentiated cell phenotype (van de
Wetering et al., 2002), our results suggest that SOX9 might
be involved in mediating part of this function. Furthermore,
SOX10, closely related to SOX9, is involved in the mainte-
nance of neural crest stem cells multipotency and inhibition
of neural differentiation (Kim et al., 2003), SOX2 maintains
precursor cells of the mouse blastocyst in a multipotent state
(Avilion et al., 2003), and SOX1–3 counteract the activity
of proneural proteins to keep neural cells undifferentiated
(Bylund et al., 2003). Thus, contribution to the mainte-
nance of cells in an undifferentiated state might be a prop-
erty shared by several SOX transcription factors, and our
finding that SOX9 is regulated by the Wnt pathway, which
is also known to inhibit differentiation, might also concern
other SOX genes.
Possible involvement of SOX9 in cancer
We found that SOX9 negatively regulates the CDX2 tumor
suppressor gene, which is frequently very weakly expressed
in colon cancers (Ee et al., 1995; Mallo et al., 1997), espe-
cially in poorly differentiated lesions (Hinoi et al., 2001).
Mice heterozygous for the CDX2 gene are hypersensitive to
sporadic, chemically induced, colon carcinogenesis (Bon-
homme et al., 2003), and this was confirmed in a mouse
model of familial adenomatous polyposis (Aoki et al., 2003).
MUC2 deficiency also leads to spontaneous intestinal
tumors (Velcich et al., 2002). Conversely, restoration of
CDX2 expression in human colon carcinoma cells sup-
pressed proliferation and soft agar growth (Hinoi et al.,
2003). Here, we find that overexpressing a dominant-nega-
tive version of SOX9 results in increased CDX2 expres-
sion in cultured colon carcinoma cells. This suggests that
strong SOX9 expression in tumors which contain a constitu-
tive activation of Wnt signaling may contribute to cancer
progression and/or determination of the level of tumor
differentiation.
In summary, we report that SOX9 is expressed through-
out the intestinal epithelium under the control of the Wnt
pathway and we propose that SOX9 function contributes to
the Wnt-dependent maintenance of undifferentiated cells in
healthy and tumor epithelial cells. The function of SOX9 in
Paneth cells, where the Wnt pathway is also active, remains
to be determined. Our finding might have implications for
other structures where SOX9 function is essential, such as
sex determination, chondrogenesis, neural crest, or nervous
system development.
Materials and methods
DNA constructs
NH2-terminally flagged wild-type and COOH-terminally truncated SOX9-
pcDNA expression constructs have been described previously (Südbeck et
al., 1996; de Santa Barbara et al., 1998). The antisense SOX9 expression
construct was generated by cloning the BamHI–EcoRI fragment containing
the SOX9 ORF from SOX9-pcDNA into the same restriction sites of
pIRESneo (CLONTECH Laboratories, Inc.) The GFP-E-cadherin construct
was a gift from A. Blangy and C. Gauthier (CNRS FRE2593, Montpellier,
France). NH2-truncated TCF4 ( N-TCF4 dominant negative) has been de-
scribed previously (van de Wetering et al., 2002) and was provided by B.
Vogelstein (Howard Hughes Medical Institute, Baltimore, MD). The SOX9-
VP16 (Kamachi et al., 1999) was provided by H. Kondoh (Institute for Mo-
lecular and Cellular Biology, Osaka University, Osaka, Japan), and the
MUC-2-luciferase reporter (Yamamoto et al., 2003) was a gift from Y.
Yuasa (Tokyo Medical and Dental University, Tokyo, Japan). The CDX-2
promoter reporter constructs were published previously (Lorentz et al.,
1999).
Cell culture and transfections
All cell lines were grown in RPMI medium supplemented with 10% FBS
(Life Technologies). Stably transfected LS174T cell lines with inducible
 NTCF4 have been described previously (van de Wetering et al., 2002).
HT29-16E human colorectal carcinoma cells were given by C. Laboisse
(INSERM U539, Nantes, France). The T-Rex
TM system (Invitrogen) was used
for the generation of stable SOX9-inducible HT29-16E cells. In brief, tetra-
cycline-inducible HT29-16E cells were obtained by stable transfection of
the regulatory plasmid pcDNA6/TR. NH2-terminally flagged SOX9 was
then inserted in pcDNA4/TO and stably transfected in the tetracycline-
inducible HT29-16E cells.
SOX9 mRNA and protein expression was analyzed 36 h after doxycy-
cline induction. For transient transfections, the LS174T colon carcinoma
cell line was transfected using Fugene 6 (Roche), according to the instruc-
tions of the supplier, and cells were lysed for analysis 36 h after transfec-
tion. Cells transfected for RT-PCR purpose were cotransfected with the
pMACS-K
k plasmid kit (Miltenyi Biotec), encoding the mouse MHC class I
molecule H-2K
k as a selection marker. Dual luciferase kit (Promega) was
used for luciferase measurement and normalization.
RNA purification and RT-PCR
Before RT-PCR experiments, transfected cells harboring the H-2K
k surface
molecule were selected using the MACSelect H-2K
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lection kit (Miltenyi Biotec). Standard procedures were used for RNA puri-
fication and reverse transcription. Each PCR amplification was repeated
several times with different numbers of cycles to ensure that the obtained
amplified products reflected the original DNA concentrations. The primers
used are listed in Table S1, available at http://www.jcb.org/cgi/content/full/
jcb.200311021/DC1.
Xenografts
Cells from the HT29-16E cell line, stably transfected with the doxycycline-
inducible Flag-SOX9 construct, were resuspended in DME medium con-
taining penicillin-streptomycin at 200 U/ml (Life Technologies). Six nude
mice were injected subcutaneously with 10
7 cells each in 50  l of culture
medium. From day 6 after cell injection until tumor removal at week 11,
200  g/ml doxycycline was administered in drinking water to three mice,
whereas the other three mice received doxycycline-free water.
Immunohistochemistry, immunofluorescence, Northern and 
Western blotting
Experiments were performed according to standard procedures. Samples
of human colon tumors were provided by C. Marty-Double (CHU, Nîmes,
France). For immunohistochemistry, Envision   (DakoCytomation) was
used as a secondary reagent, stainings were developed with DAB (brown
precipitate), and hematoxylin counterstain was used. The TCF4 K.O.
mouse has been described previously (Korinek et al., 1998). For immuno-
fluorescence experiments, nuclei were stained with Hoechst (H33258;
Sigma-Aldrich). For Western blotting, an equal amount of protein, mea-
sured by the Bradford assay, was loaded on each lane of the gel.
Antibodies
The SOX9 antibody has been described previously (de Santa Barbara et al.,
1998). The MUC2 antibody (1:1,000) was provided by I. van Seuningen
(INSERM U560, Lille, France).  -Actin A5441 and Flag (1:500) were
purchased from Sigma-Aldrich; Ki-67 was purchased from Novocastra
(1:150);  -catenin was purchased from BD Transduction Laboratories
(1:50); CDX2 was purchased from Biogenex (1:500); and Myc tag 9E10
was purchased from Santa Cruz Biotechnology, Inc. (1:100).
Image acquisition and manipulation
Immunofluorescence images were acquired at RT using a microscope
(model DMR; Leica), 40   1.0 Pl Fluotar or 63   1.32 PL Apo lenses
(Leica), and a camera (model C5985; Hamamatsu). Images were acquired
and manipulated with the Adobe Photoshop software. Fluorochromes
were Alexa 488 and 568 dyes (Molecular Probes).
Immunohistochemistry images were acquired at RT using an Axiophot
microscope (Carl Zeiss MicroImaging, Inc.), 10   0.3 Plan Neofluor or
40   1.0 Plan Apochromat lenses (Carl Zeiss MicroImaging, Inc.) and a
camera (model DXM1200; Nikon). Images were acquired and manipu-
lated respectively with the Nikon ACT-1 and Adobe Photoshop softwares.
Online supplemental material
Fig. S1 shows that the SOX9 protein is expressed only in the nucleus of
cultured colon carcinoma cells or of intestine epithelial cells. Fig. S2 con-
tains a kinetic analysis of the repression of SOX9 expression after interfer-
ence with the Wnt pathway activity. Fig. S3 shows that the SOX9 protein
acts as a negative feedback loop to inhibit the Wnt pathway activity in cul-
tured colon carcinoma cells. Table S1 is a set of oligonucleotide primers
used for RT-PCR. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200311021/DC1.
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